Treace Medical Concepts

TMCI

Market cap $175M

Treace Medical Concepts, Inc. ( TMCI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division Jayna Renee Francis - UBS Investment Bank, Research Division Presentation Trip Taylor Good afternoon, everyone, and welcome to our third quarter 2025 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.

PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.25 per share a year ago.

PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 2025.

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Investor Day Call September 3, 2025 9:00 AM EDT Company Participants John Treace - Founder, Chairman & CEO Sean Scanlan - Chief Innovation Officer Conference Call Participants William DeCarbo Mark Easley Holly Johnson Jonathan Kaplan Ryan Zimmerman - BTIG, LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Arthur Weise Danielle Antalffy - UBS Investment Bank, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Anton Heldmann - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation John Treace Founder, Chairman & CEO Good morning, everybody. We're going to go ahead and get started.

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John T. Treace - Founder, Chairman & CEO Mark L.

Treace Medical (TMCI) Q2 Revenue Up 7%

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.

PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025.